Louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely
The US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday.
Louisiana sued the US Food and Drug Administration (FDA) in October in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely, arguing that it interfered with the state’s ban on abortion.
The fifth circuit ruled in Louisiana’s favor on 1 May, effectively banning mail-order mifepristone for the entire country. Two mifepristone manufacturers, Danco Laboratories and GenBioPro, filed an emergency request with the supreme court, which granted a temporary stay until at least Thursday.
A temporary stay until at least Thursday means we’re not at the end of this. It’s going to be an issue again next week.
I’m pretty sure they were being facetious.
That’s what I get for commenting right after my wake ‘n’ bake.